Bayer Enters AI Partnership With Exscientia for Cardiovascular, Oncology Drug Discovery

Data : 09/01/2020 @ 14:07
Fonte : Dow Jones News
Titolo : Bayer AG (BAYN)
Quotazione : 74.09  0.0 (0.00%) @ 01:00
Quotazione Bayer Grafico

Bayer Enters AI Partnership With Exscientia for Cardiovascular, Oncology Drug Discovery

Grafico Azioni Bayer (XE:BAYN)
Storico

2 Mesi : Da Dic 2019 a Feb 2020

Clicca qui per i Grafici di Bayer
   By Kim Richters 
 

Bayer AG (BAYN.XE) said Thursday that it has entered a research collaboration with pharma-tech company Exscientia Ltd. to use artificial intelligence in cardiovascular and oncology drug discovery.

The German pharmaceutical and chemical giant said the companies will focus on early-stage research and use artificial intelligence to predict potential drug molecules, possibly accelerating drug discovery.

"Exscientia's AI-driven drug discovery technology provides novel chemical matter for difficult-to-address targets and could identify novel drug candidates more efficiently through less optimization cycles," Bayer said.

As part of the three-year agreement, the U.K.-based Exscientia may get up to 240 million euros ($267.1 million) as well as sales royalties, while Bayer will own the rights to lead structures generated during the collaboration.

 

Write to Kim Richters at kim.richters@wsj.com

 

(END) Dow Jones Newswires

January 09, 2020 07:52 ET (12:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
La tua Cronologia
BIT
BMPS
Monte Pasc..
BITI
FTSEMIB
FTSE Mib
BIT
UCG
Unicredit
NASDAQ
AAPL
Apple
FX
EURUSD
Euro vs Do..
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.

Registrati ora per creare la tua watchlist personalizzata in tempo reale streaming.

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

P: V:it D:20200224 06:32:48